Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (ADIA) operates at the intersection of advanced regenerative medicine and premium nutritional science. This centralized news hub provides investors and healthcare professionals with essential updates on the company's dual focus: organic supplement innovations and groundbreaking stem cell therapies.
Access timely announcements spanning regulatory milestones, clinical trial progress, and strategic partnerships. Key updates include FDA compliance developments, treatment protocol validations, and distribution network expansions through Adia Labs LLC. Our curated feed ensures transparent tracking of financial audits and operational enhancements as the company progresses toward OTCQB listing.
Bookmark this resource for verified updates on autologous stem cell treatments for multiple sclerosis, umbilical cord therapy advancements, and nutritional product line extensions. Regular monitoring recommended for stakeholders tracking healthcare innovation in regulated markets.
ADIA Nutrition (OTC Pink: ADIA) announces FDA registration acceptance for Adia Vita, its subsidiary Adia Labs' premier stem cell product. The product contains a minimum of 100 million viable cells and 3 trillion exosomes per unit.
The registration enables nationwide distribution to doctors and clinics, making advanced regenerative medicine more accessible. While typical stem cell therapies cost between $15,000-$35,000 per treatment, Adia Med aims to offer their superior product at a reduced price point.
The company is now actively expanding its reach across the United States, targeting healthcare providers and medical professionals to enhance patient care and support clinical research in various health conditions.
ADIA Nutrition Inc. (OTC Pink: ADIA) reports significant developments in February 2025, following a profitable January at its Winter Park Clinic. Key February milestones include: entering the $15.1B global stem cell market on February 3, appointing a PCAOB-registered accounting firm for OTCQB uplisting on February 5, and pledging to retire 25M undocumented shares (15% reduction) on February 11.
The company launched Adia Labs on February 20, introducing Adia Vita stem cell product. On February 24, they announced nationwide expansion through Medical Spa partnerships. By February 26, OTC Markets removed ADIA's shell risk designation, advancing their OTCQB uplisting goals.
The company's medical division, Adia Med, offers FDA-compliant stem cell treatments using umbilical cord products, targeting inflammation, autoimmune disorders, and orthopedic issues. Their Winter Park Clinic exceeded financial expectations in January 2025, covering all opening expenses with surplus revenue.
Adia Nutrition Inc. (OTC Pink: ADIA) has achieved a significant milestone by successfully removing its shell risk designation from OTC Markets, marking a important step toward uplisting from OTC Pink Sheets to the OTCQB Venture Market. This development enhances the company's market position and demonstrates its commitment to operational transparency.
The removal of the shell risk designation, a critical requirement for OTCQB status, was accomplished through close collaboration with OTC Markets. The company has been actively working to meet all uplisting criteria, including completing a comprehensive third-party audit.
CEO Larry Powalisz expressed enthusiasm about this achievement, indicating it will enable greater information sharing with investors. The OTCQB Venture Market is expected to provide enhanced transparency, liquidity, and investor trust, allowing Adia Nutrition to better showcase its stem cell therapies and nutritional products portfolio.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced a strategic nationwide expansion plan for Adia Med satellite locations through partnerships with premier Medical Spas. The initiative focuses on making their regenerative medicine treatments more accessible across the United States.
The expansion strategy involves collaborating with established Med Spas to offer Umbilical Cord Stem Cell therapies, stem cell injectables, and other regenerative solutions. The company will implement a phased approach, starting with pilot programs in major cities and affluent suburbs with health-conscious demographics.
The business model includes multiple revenue streams through service fees, royalties, and potential equity interests. ADIA will provide comprehensive training and quality control measures to maintain consistent treatment standards across all locations. CEO Larry Powalisz emphasized that successful Med Spas will benefit from a generous commission structure and increased patient base.
ADIA Nutrition (OTC Pink: ADIA) has launched Adia Labs , a new division focused on regenerative medicine. The company introduces two key products: AdiaVita, a private-label umbilical cord stem cell product guaranteeing 100 million viable cells and 3 trillion exosomes per unit, and AdiaLink, an upcoming product offering 3.5 trillion exosomes per unit.
The launch was enabled through a partnership with an FDA-approved laboratory, allowing ADIA to offer these products under its own brand. The products are specifically designed for clinical research, studies, and trials, targeting a potential client base of over one million doctors and clinics nationwide.
These products aim to address various conditions, including autoimmune diseases, degenerative disorders, and injury recovery, focusing on non-invasive biological treatments. Doctors and clinics can purchase these products through adialabs.com.
Adia (ADIA) has announced a strategic partnership with an FDA-approved laboratory specializing in regenerative medicine. The collaboration focuses on providing high-quality umbilical cord stem cell and exosome products. The lab's products feature 100 million umbilical cord stem cells and 3 trillion exosomes per dose.
The partnership highlights several key attributes: FDA approval ensuring safety and quality protocols for biologics, third-party verification for product quality, minimal manipulation techniques to preserve therapeutic properties, and research excellence in identifying optimal umbilical cord stem cell sources. The products are intended for various therapeutic applications, including orthopedics, neurology, and dermatology.
The company aims to distribute these advanced products for clinical trials, therapeutic use, and preventive medicine applications, particularly in anti-aging and wellness treatments.
Adia Med, the medical division of Adia Nutrition (OTC Pink: ADIA), is pursuing registration with Florida's Agency for Health Care Administration (AHCA) to accept private insurance for its stem cell therapies. This initiative aims to expand access to their Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and injectable stem cell treatments.
Currently operating on an out-of-pocket payment model, the company aims to reduce financial barriers through insurance coverage. The company has engaged specialized consultants for AHCA registration and financial documentation. Multiple potential clients have already received preapproval from private insurers for both HSCT and injectable stem cell therapies, indicating growing acceptance of these treatments in the insurance industry.
ADIA Nutrition Inc. (OTC Pink: ADIA) has discovered issues with approximately 25 million shares issued or committed without proper documentation over a decade ago. This includes 15 million currently outstanding shares and 10 million shares promised in a payment agreement before the current board's tenure. The company plans to retire these shares, which would reduce outstanding shares by about 15%.
Current share structure shows: 95,899,861 outstanding shares, 74,051,080 restricted shares, 21,848,781 unrestricted shares, 19,575,347 shares held at DTC, and a float of 13,848,781. The company is investigating additional restricted shares that might have been improperly issued. Management is working with legal advisors to properly retire the shares while maintaining operational focus on health and wellness initiatives, including umbilical cord stem cell treatments and HSCT for Multiple Sclerosis.
Adia Nutrition (OTC Pink: ADIA) has appointed a PCAOB accounting firm for a comprehensive third-party audit as part of its strategy to uplist from OTC Pink Sheets to the OTCQB Venture Market. This move aims to enhance visibility and attract more investors while demonstrating the company's commitment to transparency.
The uplisting to OTCQB is expected to provide several benefits, including increased transparency through higher reporting standards, greater market liquidity, enhanced investor confidence, and broader accessibility to investors. The company has outlined a roadmap to eventually list on the Nasdaq Small Cap, which involves completing the OTCQB uplisting, establishing SEC reporting, scaling operations to meet Nasdaq's standards, and ensuring adequate shareholder equity and public float.
Adia Nutrition (OTC Pink: ADIA) has entered the $15.1 billion global stem cell market through its medical division, Adia Med, with the opening of its first clinic in Winter Park, Florida. The facility offers stem cell treatments using FDA-compliant 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps).
The company aims to provide treatments comparable to international locations like Panama, Mexico, Brazil, and Switzerland, but with the advantage of U.S.-based care. The clinic utilizes umbilical cord stem cells and focuses on treating conditions including inflammation, autoimmune conditions, and orthopedic issues.
Key advantages include quality stem cells from ethical sources, domestic convenience eliminating international travel, and operations under U.S. FDA health regulations emphasizing safety and transparency.
